[CAS NO. 59-46-1] Procaine
PRODUCTS SPECIFICATIONS [59-46-1]
DESCRIPTION [59-46-1]
Overview
| MDL | MFCD00007893 |
|---|---|
| Molecular Weight | 236.31 |
| Molecular Formula | C13H20N2O2 |
| SMILES | O=C(OCCN(CC)CC)C1=CC=C(N)C=C1 |
1 Publications Citing Use of MCE
Summary
In Vitro
Procaine (0.01-100 microM) inhibited the 5-HT3 receptor-mediated inward current in the whole-cell patch clamp recording. Procaine appears to produce a competitive inhibition on 5-HT3 receptors with a KD of 1.7 microM [1] . Procaine is a DNA-demethylating agent that produces a 40% reduction in 5-methylcytosine DNA content as determined by high-performance capillary electrophoresis or total DNA enzyme digestion. Procaine can also demethylate densely hypermethylated CpG islands. Procaine also has growth-inhibitory effects in these cancer cells, causing mitotic arrest [2] . Procaine functions as an excitant of limbic system cells, and that procaine alters synaptic transmission in some, but not all, output pathways from the amygdale [3] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT03838068 | Gihan M Abuelniel ,PhD|Cairo University |
Pulp Exposure, Dental
|
January 18, 2017 | Phase 2|Phase 3 |
| NCT02735317 | Yun-fei Xia|Sun Yat-sen University |
Nasopharyngeal Neoplasms|Stomatitis
|
April 2016 | Phase 2 |
| NCT01027429 | Aga Khan University|Save the Children|World Health Organization|London School of Hygiene and Tropical Medicine|Emory University |
Neonatal Sepsis|Sepsis|Infection
|
December 2009 | Phase 3 |
| NCT00189384 | Aga Khan University |
Bacterial Infection|Sepsis|Infant, Newborn
|
November 2003 | Phase 3 |
| NCT02726620 | Vanderbilt University Medical Center|UMC Utrecht |
Hypotension
|
January 5, 2017 | Not Applicable |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years |
* The compound is unstable in solutions, freshly prepared is recommended.
Solvent & Solubility
DMSO : 100 mg/mL ( 423.17 mM ; Need ultrasonic)
H 2 O : 1 mg/mL ( 4.23 mM ; ultrasonic and warming and heat to 60°C)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 4.2317 mL | 21.1586 mL | 42.3173 mL |
| 5 mM | 0.8463 mL | 4.2317 mL | 8.4635 mL |
| 10 mM | 0.4232 mL | 2.1159 mL | 4.2317 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (10.58 mM); Clear solution
-
3.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (10.58 mM); Clear solution
-
4.
Add each solvent one by one: PBS
Solubility: 2 mg/mL (8.46 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
References
- [1] Fan, P. and F.F. Weight, Procaine impairs the function of 5-HT3 receptor-ion channel complex in rat sensory ganglion neurons. Neuropharmacology, 1994. 33(12): p. 1573-9.
- [2] Villar-Garea, A., et al., Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. Cancer Res, 2003. 63(16): p. 4984-9.
- [3] Adamec, R.E. and C. Stark-Adamec, The effects of procaine HCl on population cellular and evoked response activity within the limbic system of the cat. Evidence for differential excitatory action of procaine in a variety of limbic circuits. Prog Neuropsychopharmacol Biol Psychiatry, 1987. 11(4): p. 345-64.
Synonyms